Barchart on MSN
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?
Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain ...
18h
Kidney Disease Trial Success Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary membranous nephropathy, showing significant proteinuria reduction and ...
Columbia Cornerstone Equity Fund Institutional Class shares returned 7.56% for the three months ending September 30, 2025.
Equities surged in Q3 2025, but our Large Cap Growth Portfolios underperformed due to AI positioning. Click here to read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback